Castle Biosciences Reports Second Quarter 2026 Results
PR Newswire•30/07/2026•16:05 ET
0
Whiz Insights
Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx(®)-Melanoma, TissueCypher(®)) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to $365-375 million from $345-355 million Conference call and webcast today at 4:30 p.m. ET
FRIENDSWOOD, Texas, July 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter ended June 30, 2026.
Get started
Create a free account to read the full story.